Skip to main content
Premium Trial:

Request an Annual Quote

CST, AstraZeneca Ink Third Phosphorylation-Profiling Deal

NEW YORK, April 12 (GenomeWeb News) - Cell Signaling Technology has signed a third agreement with AstraZeneca to continue providing the drug maker with phosphorylation profiles and prospective biomarkers of kinase-targeted lead compounds, the company said today.

 

CST announced similar agreements this January and in June 2004.

 

According to its most recent statement, it will use its PhosphoScan technology to provide AstraZeneca with information that could enable it to clinically develop biomarker assays for target validation and therapeutic kinase inhibitors.

 

CST also said that it has recently added methods for serine/threonine kinase PhosphoScan profiling to its capabilities.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.